Trials / Completed
CompletedNCT04161911
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
Overall Survival and Treatment Patterns for Advanced Hepatocellular Carcinoma Patients Who Received Second or Third Line Nivolumab Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,426 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
Detailed description
The central aims of this study are descriptive and designed to describe the patient demographics, clinical characteristics, treatment patterns, and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy in the real-world setting.
Conditions
Timeline
- Start date
- 2018-10-29
- Primary completion
- 2018-11-15
- Completion
- 2018-11-19
- First posted
- 2019-11-13
- Last updated
- 2019-11-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04161911. Inclusion in this directory is not an endorsement.